Global Irritable Bowel Syndrome (IBS) Market, By Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Others), Medical Condition (IBS-Constipation, IBS-diarrhea, Mixed), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End-Users (Hospitals, Clinics, Homecare Settings), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029
Market Analysis and Insights Global Irritable Bowel Syndrome (IBS) Market
The irritable bowel syndrome (IBS) market is expected to witness market growth at a rate of 12.90% in the forecast period of 2022 to 2029. Data Bridge Market Research report on irritable bowel syndrome (IBS) market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the prevalence of chronic diseases globally is escalating the growth of irritable bowel syndrome (IBS) market.
Irritable bowel syndrome (IBS) refers to a common gastrointestinal disorder that tends to affect the large intestine. Abdominal pain, gas, constipation or diarrhea, bloating and cramping are some of the Signs and symptoms of IBS. There are three types of irritable bowel syndrome such as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), and Mixed IBS.
The rise in prevalence of irritable bowel syndrome (IBS) across the globe acts as one of the major factors driving the growth of irritable bowel syndrome (IBS) market. The rise in in level of stress due to hectic and busy lifestyle, and increase in awareness programs regarding the treatment and management of irritable bowel syndrome accelerate the market growth. The increase in prevalence of gastrointestinal diseases and disorders such as alteration of bowel habit and abdominal pain, and adoption of unhealthy diet further influence the market. Additionally, rise in population, surge in healthcare expenditure, development in technology, increase in research and development, and rise in geriatric population positively affect the irritable bowel syndrome (IBS) market. Furthermore, inclination toward IBS products that enhance therapeutic outcome extend profitable opportunities to the market players in the forecast period of 2022 to 2029.
On the other hand, lack of specific treatment that treat all the symptoms of the IBS disorder is expected to obstruct the market growth. The high competition among the key players is projected to challenge the irritable bowel syndrome (IBS) market in the forecast period of 2022-2029.
This irritable bowel syndrome (IBS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info irritable bowel syndrome (IBS) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Irritable Bowel Syndrome (IBS) Market Scope and Market Size
The irritable bowel syndrome (IBS) market is segmented on the basis of drug type, medical edition, distribution channel and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug type, the irritable bowel syndrome (IBS) market is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, alosetron and others.
- On the basis of medical edition, the irritable bowel syndrome (IBS) market is segmented into IBS-constipation, IBS-diarrhea and mixed.
- On the basis of distribution channel, the irritable bowel syndrome (IBS) market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies.
- On the basis of end-users, the irritable bowel syndrome (IBS) market is segmented into hospital pharmacy, clinics, retail pharmacies and online sales.
Irritable Bowel Syndrome (IBS) Market Country Level Analysis
The irritable bowel syndrome (IBS) market is analyzed and market size information is provided by country, drug type, medical edition, distribution channel and end-users as referenced above.
The countries covered in the global irritable bowel syndrome (IBS) market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the irritable bowel syndrome (IBS) market due to the presence of developed healthcare infrastructure within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the large population in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The irritable bowel syndrome (IBS) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Irritable Bowel Syndrome (IBS) Market Share Analysis
The irritable bowel syndrome (IBS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related irritable bowel syndrome (IBS) market.
Some of the major players operating in the irritable bowel syndrome (IBS) market report are Ironwood Pharmaceuticals, Inc., Allergan, Astellas Pharma, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sebela Pharmaceuticals Inc., Synergy Pharmaceuticals In., Bausch Health, Synthetic Biologics, Inc., Ardelyx., Salix Pharmaceuticals, Mallinckrodt., Abbott Laboratories, LEXICON PHARMACEUTICALS, INC, GlaxoSmithKline plc, Johnson & Johnson Services, Inc, Ono Pharmaceutical Co., Ltd., Pfizer Inc, Novartis and Sebela Pharmaceuticals Inc., among others.
SKU-